Antimicrobial use in Canadian acute-care hospitals: Findings from three national point-prevalence surveys between 2002 and 2017.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 8 3 2022
medline: 22 11 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

The Canadian Nosocomial Infection Surveillance Program conducted point-prevalence surveys in acute-care hospitals in 2002, 2009, and 2017 to identify trends in antimicrobial use. Eligible inpatients were identified from a 24-hour period in February of each survey year. Patients were eligible (1) if they were admitted for ≥48 hours or (2) if they had been admitted to the hospital within a month. Chart reviews were conducted. We calculated the prevalence of antimicrobial use as follows: patients receiving ≥1 antimicrobial during survey period per number of patients surveyed × 100%. In each survey, 28-47 hospitals participated. In 2002, 2,460 (36.5%; 95% CI, 35.3%-37.6%) of 6,747 surveyed patients received ≥1 antimicrobial. In 2009, 3,566 (40.1%, 95% CI, 39.0%-41.1%) of 8,902 patients received ≥1 antimicrobial. In 2017, 3,936 (39.6%, 95% CI, 38.7%-40.6%) of 9,929 patients received ≥1 antimicrobial. Among patients who received ≥1 antimicrobial, penicillin use increased 36.8% between 2002 and 2017, and third-generation cephalosporin use increased from 13.9% to 18.1% ( The prevalence of antimicrobial use increased between 2002 and 2009 and then stabilized between 2009 and 2017. These data provide important information for antimicrobial stewardship programs.

Identifiants

pubmed: 35249564
pii: S0899823X21005195
doi: 10.1017/ice.2021.519
pmc: PMC9672830
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1558-1564

Références

Clin Infect Dis. 2007 Sep 1;45 Suppl 2:S112-21
pubmed: 17683015
N Engl J Med. 2005 Dec 8;353(23):2442-9
pubmed: 16322602
JAMA. 2014 Oct 8;312(14):1438-46
pubmed: 25291579
CMAJ. 2018 Jun 25;190(25):E758-E765
pubmed: 29941432
Can J Infect Dis Med Microbiol. 2008 May;19(3):237-42
pubmed: 19412381
CMAJ. 2019 Sep 9;191(36):E981-E988
pubmed: 31501180
Infect Control Hosp Epidemiol. 2018 Mar;39(3):350-354
pubmed: 29378669
BMJ. 2008 Jul 15;337:a816
pubmed: 18632714
Infect Chemother. 2016 Dec;48(4):267-273
pubmed: 28032484
Infect Control Hosp Epidemiol. 2019 Aug;40(8):920-921
pubmed: 31182182
Euro Surveill. 2018 Nov;23(46):
pubmed: 30458917
Lancet Microbe. 2021 May;2(5):e182-e190
pubmed: 35544207
Can Commun Dis Rep. 2020 May 07;46(5):99-112
pubmed: 32558807
Lancet Glob Health. 2018 Jun;6(6):e619-e629
pubmed: 29681513
CMAJ Open. 2018 Feb 2;6(1):E71-E76
pubmed: 29420185
Infect Control Hosp Epidemiol. 2012 Jun;33(6):594-601
pubmed: 22561715
Nat Microbiol. 2019 Nov;4(11):1919-1929
pubmed: 31358985
Antimicrob Resist Infect Control. 2020 Feb 13;9(1):32
pubmed: 32054539

Auteurs

Jennifer J Liang (JJ)

Public Health Agency of Canada, Ottawa, Ontario, Canada.

Wallis Rudnick (W)

Public Health Agency of Canada, Ottawa, Ontario, Canada.

Robyn Mitchell (R)

Public Health Agency of Canada, Ottawa, Ontario, Canada.

James Brooks (J)

Public Health Agency of Canada, Ottawa, Ontario, Canada.

Kathryn Bush (K)

Alberta Health Services, Calgary, Alberta, Canada.

John Conly (J)

Alberta Health Services, Calgary, Alberta, Canada.
University of Calgary, Calgary, Alberta, Canada.

Jennifer Ellison (J)

Alberta Health Services, Calgary, Alberta, Canada.

Charles Frenette (C)

McGill University Health Centre, Montréal, Québec, Canada.

Lynn Johnston (L)

Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.

Christian Lavallée (C)

Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.

Allison McGeer (A)

Sinai Health Systems, Toronto, Ontario, Canada.

Dominik Mertz (D)

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Hamilton Health Sciences, Hamilton, Ontario, Canada.

Linda Pelude (L)

Public Health Agency of Canada, Ottawa, Ontario, Canada.

Michelle Science (M)

Hospital for Sick Children, Toronto, Ontario, Canada.

Andrew Simor (A)

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Stephanie Smith (S)

University of Alberta Hospital, Edmonton, Alberta, Canada.

Paula Stagg (P)

Western Memorial Regional Hospital, Corner Brook, Newfoundland, Canada.

Kathryn N Suh (KN)

The Ottawa Hospital, Ottawa, Ontario, Canada.

Nisha Thampi (N)

Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Daniel J G Thirion (DJG)

McGill University Health Centre, Montréal, Québec, Canada.
Université de Montréal, Montréal, Québec, Canada.

Joseph Vayalumkal (J)

Alberta Health Services, Calgary, Alberta, Canada.
University of Calgary, Calgary, Alberta, Canada.
Alberta Children's Hospital, Calgary, Alberta, Canada.

Alice Wong (A)

Royal University Hospital, Saskatoon, Saskatchewan, Canada.

Geoffrey Taylor (G)

University of Alberta Hospital, Edmonton, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH